The FDA’s top vaccine regulator is returning to his post less than 2 weeks after the White House had him ousted.

CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out ...

Internally, records released this month revealed that Prasad had overridden career FDA staff to limit emergency use approvals for updated shots from Moderna and Novavax.

Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...

Vinay Prasad is back at the FDA, and in a position in which grappling with nuance — not always his strong suit — will be the ...

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

At the U.S. Food and Drug Administration's (FDA) request, Vinay Prasad is returning to the role of director of the Center for ...

Vinay Prasad, previously critical of U.S. COVID-19 policies, has returned to his role managing vaccine and gene therapy regulation at the FDA, days after his departure. His leadership saw controversy ...

Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...

The Food and Drug Administration's polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of biotech executives, patient groups and conservative allies of President ...

Vinay Prasad's exit signals FDA's probable slip toward more permissive regulation of cell and gene therapy: analyst By Angus Liu Jul 31, 2025 9:10am U.S. FDA CBER Vinay Prasad Cell & Gene Therapy ...

Why Vinay Prasad Had to Go at FDA The gene therapy chief wanted to block fast-track drug approvals. By The Editorial Board Follow ...